Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Malaria vaccine trial: an interview with Professor Sir Brian Greenwood

Malaria is an infection caused by a parasite called plasmodium, which is transmitted from person to person by females of some species of mosquito. It is primarily a disease of tropical countries.

14 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

The pharmaceutical industry is experiencing a massive paradigm shift as the era of the highly profitable blockbusters comes to a close. In an attempt to remain competitive, companies are under more pressure than ever to push novel compounds through the development pipeline and so it has been largely left to those in formulation and delivery to optimise their product portfolio using winning business strategies and leading technologies.

10 Dec 2012

Novel organic metamaterial holds promise for drug delivery

A bit reminiscent of the Terminator T-1000, a new material created by Cornell researchers is so soft that it can flow like a liquid and then, strangely, return to its original shape.

7 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells.

5 Dec 2012

University of Washington team develops electrically spun cloth to prevent pregnancy, HIV

The only way to protect against HIV and unintended pregnancy today is the condom. It's an effective technology, but not appropriate or popular in all situations.

1 Dec 2012

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision Incorporated today announced that patient enrollment has been completed in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

29 Nov 2012

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

During IVF treatment you will need to take certain drugs. For example, for IVF it will be Follicle Stimulating Hormones (FSH) which are used to stimulate the ovaries to produce a mature egg so that they can be fertilised externally and then put back into the womb.

29 Nov 2012

Tufts University researchers demonstrate silk-based implantable optics

Tufts University School of Engineering researchers have demonstrated silk-based implantable optics that offer significant improvement in tissue imaging while simultaneously enabling photo thermal therapy, administering drugs and monitoring drug delivery. The devices also lend themselves to a variety of other biomedical functions.

29 Nov 2012

Solvias, Hovione partner to develop and supply pharmaceutical co-crystals

Hovione and Solvias today announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. This strengthens Hovione's expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias' excellence in solid state chemistry.

28 Nov 2012

Grove professor to investigate personalized therapies against breast cancer

For some time, researchers have known about disparities in diagnoses and outcomes among breast cancer patients based on race and age. However, they have been challenged to develop a set of criteria that can be used to reliably target drug delivery mechanisms based on an individual patient's tumor.

27 Nov 2012

UPC teams conduct research in biomedical engineering to improve people's health

Systems to improve patient rehabilitation, methods that help detect diseases, and smart biomaterials for optimising treatments—scientific advances in the field of biomedical engineering are unstoppable. A number of leading UPC teams are carrying out research aimed at harnessing technology to improve people's health.

23 Nov 2012

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio.

20 Nov 2012

FDA accepts Orexo’s Zubsolv NDA for review

FDA has informed Orexo that the Zubsolv New Drug Application (NDA) has been accepted for review, and that the Prescription Drug User Fee Act (PDUFA) action date will be July 6, 2013.

19 Nov 2012

Shear thinning hydrogels hold promise in treating many diseases, including cancer

Gels that can be injected into the body, carrying drugs or cells that regenerate damaged tissue, hold promise for treating many types of disease, including cancer. However, these injectable gels don't always maintain their solid structure once inside the body.

16 Nov 2012

Tanshinones protect against sepsis: Study

Researchers at The Feinstein Institute for Medical Research have discovered that tanshinones, which come from the plant Danshen and are highly valued in Chinese traditional medicine, protect against the life-threatening condition sepsis. The findings are published in the December issue of Biochemical Pharmacology.

16 Nov 2012